Ageing, Resilience and the Mystery of the Super-Agers
Commentary by Dr. Donald Greig
How “Super-Agers” May Stay Healthy Beyond 100
I recently read a fascinating article about so-called “super-agers” - people who live not only beyond 100, but often remain remarkably healthy and resilient while doing so.
For decades, scientists have been asking one of medicine’s most intriguing questions: why do some people age so much more successfully than others? Is it genetics? Lifestyle? Luck? Or are there biological defence systems that help protect certain individuals from the diseases we usually associate with ageing?
A new study from researchers at the University of Osaka, published in Cell Reports, offers a compelling clue. It suggests that in some of the world’s oldest people, the immune system may not simply be “wearing out” with age. Instead, it may be reorganising itself in a highly adaptive way. (sciencedirect.com)
Ageing Is Not Just Decline
We often think of ageing as a process of gradual loss: weaker muscles, slower healing, more inflammation, reduced immunity and rising vulnerability to cancer, infection and frailty.
There is truth in that. As we age, the immune system can become less efficient. It may respond less strongly to new infections, become less precise in distinguishing friend from foe, and contribute to chronic low-grade inflammation. This process is sometimes described as immunosenescence.
But the story may be more nuanced.
The Osaka research team studied blood samples from people aged 70 and above, including centenarians aged 100–109 and supercentenarians aged 110 or older. Their focus was on T cells, a crucial part of the immune system. T cells help the body recognise infection, coordinate immune responses, remember past threats and, in some cases, directly kill infected or abnormal cells.
The Unusual Immune Cells Found in Supercentenarians
The key finding was the expansion of a normally rare immune-cell population called CD4 cytotoxic T lymphocytes, or CD4 CTLs.
Most people have heard of T cells in broad terms, but CD4 CTLs are more specialised. Traditional CD4 T cells are often described as “helper” cells because they help organise the immune response. Cytotoxic T cells, by contrast, are “killer” cells — able to destroy infected, damaged or abnormal cells.
CD4 CTLs blur that boundary. They are CD4 cells with cytotoxic, cell-killing properties.
In the Osaka study, these cells became much more common in the very oldest participants. CD4 CTLs made up a median of around 4% of T cells in people aged 70–99, rising to 9.6% in centenarians and 17.6% in those aged over 110.
That is striking because it suggests that extreme old age may be associated not merely with immune exhaustion, but with immune remodelling — the body changing the composition of its defences in response to the challenges of very long life.
Why Might These Cells Matter?
The researchers believe these expanded CD4 CTLs may help supercentenarians deal with age-related threats such as persistent viral infections, abnormal cells and possibly senescent cells.
Senescent cells are sometimes called “zombie cells.” They no longer divide normally, but they do not die when they should. Over time, they can accumulate and release inflammatory signals that may contribute to tissue damage, frailty and age-related disease.
Much anti-ageing research has focused on trying to remove these cells using drugs known as senolytics. But this study raises an intriguing possibility: perhaps some exceptionally long-lived people have immune systems that are naturally better at recognising or controlling these troublesome cells.
That remains a hypothesis, not a proven treatment pathway. But it is an exciting one.
A Possible Link With Cancer Surveillance
One of the most fascinating parts of the study was the comparison between the CD4 CTLs found in supercentenarians and T cells found in patients with cancers such as lung, breast and liver cancer.
The researchers identified similarities in the molecular “sensors” used by these immune cells. In other words, some of the T-cell receptor patterns found in supercentenarians resembled those seen in tumour-associated immune responses, even though the supercentenarians in the study had not been diagnosed with those cancers. (pubmed.ncbi.nlm.nih.gov)
This does not mean these people secretly had cancer, nor does it prove that CD4 CTLs prevent cancer.
But it does raise a compelling question: could these immune cells be helping to detect and eliminate abnormal cells before they become clinically apparent?
If so, this may represent one biological mechanism behind healthy extreme longevity - not avoiding biological threats altogether, but responding to them unusually well.
What This Does Not Mean
As exciting as this research is, it is important not to overstate it.
This was a small study, involving 28 participants. Only ten were supercentenarians aged 110 or over. That is understandable:— people in this age group are extremely rare, but it means the findings need further validation.
It also does not tell us how to become a supercentenarian. We cannot simply “boost” these cells with a supplement, diet, injection or lifestyle trick. Nor should this be interpreted as evidence for any commercial anti-ageing product.
The study provides a biological clue, not a patient-ready intervention.
The next stage will be to understand exactly what these CD4 CTLs recognise, what activates them, whether they genuinely protect against cancer, infection or senescent cells, and whether their function can be safely mimicked in future therapies.
The Wider Ageing Science Landscape
This research sits within a much broader field of ageing science.
Some researchers are exploring cell “rejuvenation” - ways of restoring more youthful function to ageing cells. Others are investigating senolytics, drugs designed to clear senescent cells. There is also growing interest in inflammation, metabolism, mitochondrial function, DNA repair, protein stability and the microbiome.
But what makes the Osaka study especially interesting is that it focuses on the immune system not as a failing structure, but as a dynamic system that may adapt under extreme conditions.
That changes the tone of the ageing conversation.
Healthy ageing may not simply be about slowing decline. It may also be about preserving adaptability.
What Can Patients Take From This?
For now, this research does not change every day medical advice.
The foundations of healthy ageing remain familiar:
Regular physical activity
Strength and balance training
A varied, nutrient-rich diet
Not smoking
Sensible alcohol intake
Good sleep
Vaccination where appropriate
Blood pressure, cholesterol and diabetes control
Cancer screening when indicated
Social connection and cognitive engagement
These may sound less glamorous than a new immune-cell discovery, but they remain the most evidence-based tools we currently have for living longer and better.
What the supercentenarian research adds is a sense of possibility. It reminds us that ageing is biologically complex, and that the oldest, healthiest individuals may carry clues that could one day help us prevent frailty, cancer and chronic disease more effectively.
A Broader Reflection
Medicine often advances by studying disease. We examine why organs fail, why cancers grow, why infections overwhelm, why memory fades.
But there is equal value in studying resilience.
Supercentenarians are not simply people who have avoided death for longer than most. They may be living examples of protective biology - people whose bodies have found unusually effective ways to adapt, repair and defend.
This study does not offer a simple answer to ageing. It does not give us a pill, a protocol or a promise.
But it does offer something intellectually powerful: a glimpse into how the human body may reorganise itself to survive extreme old age.
And perhaps that is where some of the most hopeful science lies, not in denying ageing, but in understanding why, for a rare few, ageing unfolds with such remarkable resilience.
Disclaimer: This newsletter is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for any medical concerns.
How ‘super-agers’ may stay healthy beyond 100
By Rhys Blakely
A rare type of immune cell may be a key weapon that helps a select band of “supercentenarians” stay remarkably healthy well beyond 100.
Scientists have spent decades, and billions of dollars, trying to discover why some people age so much more successfully than others, and whether the biology that protects them could be harnessed to help the rest of us.
The quest has taken researchers in several directions. Some are studying methods of “rejuvenating” cells to restore youthful resilience. Others are working with senolytics, drugs that are designed to clear away so-called senescent cells that stop dividing but refuse to die. Normally, these “zombie cells” accumulate with age, oozing toxins and contributing to harmful inflammation, frailty and disease.
The new study, published in the journal Cell Reports, asked a different question: how does the immune system alter over time in people who stay remarkably fit while leading exceptionally long lives?
Researchers at the University of Osaka in Japan found signs that the body’s natural defences were reorganising themselves as people entered their 11th decade.
The work focused on T cells, a key aspect of the immune system. Some types of T cell directly kill infected or cancerous cells by recognising specific molecular targets on their surface. Other kinds co-ordinate the broader immune response by activating or restraining other immune cells and helping the body remember threats it has encountered before.
In the super-agers, one normally rare type, known as CD4 cytotoxic T lymphocytes, or CD4 CTLs, became much more abundant. The research team believes they may help very old people deal with viruses and clear the body of senescent cells.
Most intriguingly, there were also hints that in the supercentenarians these cells may have been involved in fighting cancer at a very early stage, before it had become clinically detectable.
“It may be that immune changes in extreme old age are better understood as the immune system reorganising itself rather than just wearing out,” said Kosuke Hashimoto, an associate professor at the University of Osaka and the study’s lead author.
Hashimoto and his team analysed blood samples from 28 people. Eight were aged between 70 and 99, ten were aged 100 to 109 and ten were supercentenarians aged 110 or over.
CD4 CTLs made up a median of 4 per cent of T cells in the youngest group. That rose to 9.6 per cent among centenarians and 17.6 per cent in those aged over 110.
“CD4 CTLs are an atypical and relatively rare T cell population,” Hashimoto said. “So, their marked increase in supercentenarians may provide important clues as to how the immune system is maintained in extreme old age.”
The most striking finding came when the researchers compared the super-agers’ CD4 CTL cells with T cells from younger patients with lung, breast and liver cancers. There were key resemblances between them, even though the centenarians and supercentenarians involved in the study had never been diagnosed with those cancers.
“The similarity … suggests that these cells may help recognise tumours before they become clinically detectable,” Hashimoto said.
The researchers now aim to discover exactly what it is that the super-agers’ cells recognise and attack. The hope is that this can lead to the development of drugs that work in a similar way to tackle hidden tumours or lingering infections.
Disclaimer: This newsletter is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider for any medical concerns.
Comments